Verona Pharma Acquired by Merck for $10 Billion

Verona Pharma ( (VRNA) ) has provided an announcement.

On July 8, 2025, Verona Pharma entered into a Transaction Agreement with Merck, under which Merck, through a subsidiary, will acquire Verona Pharma for approximately $10 billion. This acquisition will add Ohtuvayre® (ensifentrine), a novel COPD treatment, to Merck’s cardio-pulmonary portfolio, aligning with its science-led business strategy. The transaction, approved by both companies’ boards, is expected to close in the fourth quarter of 2025, subject to regulatory and shareholder approvals. The acquisition is anticipated to enhance Merck’s growth and provide value to Verona Pharma’s shareholders, while expanding the reach of Ohtuvayre to more COPD patients.

The most recent analyst rating on (VRNA) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Verona Pharma stock, see the VRNA Stock Forecast page.

Spark’s Take on VRNA Stock

According to Spark, TipRanks’ AI Analyst, VRNA is a Neutral.

Verona Pharma’s stock is bolstered by strong revenue growth and a successful product launch, contributing to positive momentum. However, profitability challenges, high valuations, and potential overbought conditions temper enthusiasm. The company’s improved financial flexibility is a key strength, though ongoing operating losses and high SG&A expenses are notable risks.

To see Spark’s full report on VRNA stock, click here.

More about Verona Pharma

Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for chronic respiratory diseases, with its first commercial product being Ohtuvayre® (ensifentrine), an inhaled therapy for COPD that combines bronchodilator and non-steroidal anti-inflammatory activities.

Average Trading Volume: 1,290,436

Technical Sentiment Signal: Buy

Current Market Cap: $7.76B

See more insights into VRNA stock on TipRanks’ Stock Analysis page.